Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/13/2795402/0/en/Black-Diamond-Therapeutics-Announces-Topline-Results-from-Phase-1-Dose-Escalation-Trial-of-BDTX-1535-in-Patients-with-Recurrent-GBM.html

Initial results show promising clinical activity in heavily pretreated patients

22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months

Read more at globenewswire.com

Related news for (BDTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.